Publication date: Sep 18, 2024
Prior to the introduction of COVID-19 vaccines, patients with severe mental illness (SMI) were at greater risk of COVID-19-related outcomes than the general population. It is not yet clear whether COVID-19 vaccines have reduced the risk gap. We systematically searched nine international databases and three Chinese databases to identify relevant studies from December 2020 to December 2023 to compare the risk of COVID-19-related outcomes for SMI patients to those without SMI after vaccination. Random effects meta-analysis was performed to estimate the pooled odds ratio (OR) with 95% confidence intervals (CI). Subgroup analysis, sensitivity analysis, and publication bias analysis were conducted with R software 4. 3.0. A total of 11 observational studies were included. Compared with controls, SMI patients were associated with a slightly increased risk of infection (pooled OR = 1. 10, 95% CI, 1. 03-1. 17, I = 43. 4%), while showing a 2-fold higher risk of hospitalization (pooled OR = 2. 66, 95% CI, 1. 13-6. 22, I = 99. 6%), even after both groups have received COVID-19 vaccines. Limited evidence suggests a higher mortality risk among SMI patients compared to controls post vaccination, but the findings did not reach statistical significance. SMI patients remain at increased risk compared to their peers in COVID-19-related outcomes even after vaccination. Vaccination appears an effective approach to prevent severe COVID-19 illness in SMI patients, and actions should be taken by healthcare providers to improve vaccination coverage in these vulnerable groups.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Chinese | bipolar disorder |
| December | COVID-19 vaccines |
| Hospitalization | major depressive disorder |
| Vaccines | schizophrenia |
| severe mental illness |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Mental Illness |
| disease | MESH | COVID-19 |
| disease | MESH | infection |
| drug | DRUGBANK | Troleandomycin |
| disease | MESH | schizophrenia |
| disease | MESH | bipolar disorder |
| disease | MESH | major depressive disorder |
| disease | MESH | psychotic disorders |
| drug | DRUGBANK | Coenzyme M |
| disease | IDO | intervention |
| disease | IDO | protein |
| disease | MESH | death |
| drug | DRUGBANK | Indoleacetic acid |
| pathway | REACTOME | Immune System |
| disease | MESH | fatal outcomes |
| disease | MESH | emergency |
| disease | IDO | quality |
| disease | MESH | depression |
| disease | MESH | anxiety |
| disease | MESH | sleep disorders |
| disease | MESH | comorbidity |
| drug | DRUGBANK | Trestolone |
| disease | MESH | Sequelae |
| disease | MESH | re infection |
| drug | DRUGBANK | Huperzine B |
| pathway | KEGG | Coronavirus disease |
| drug | DRUGBANK | L-Aspartic Acid |
| disease | MESH | Breakthrough Infection |
| drug | DRUGBANK | (S)-Des-Me-Ampa |
| disease | MESH | Cardiovascular Disease |
| disease | MESH | Insomnia Disorder |
| disease | MESH | chronic diseases |